Karoline V Gleixner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/360327/publications.pdf

Version: 2024-02-01

42	1,496	393982 19	329751 37
papers	citations	h-index	g-index

42	42	42	1963
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hereditary Î± tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood, 2021, 137, 238-247.	0.6	113
2	Emicizumab for the treatment of acquired hemophilia A. Blood, 2021, 137, 410-419.	0.6	83
3	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 3176-3187.	3.3	8
4	Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. American Journal of Hematology, 2021, 96, 719-726.	2.0	1
5	Successful treatment of vaccineâ€induced prothrombotic immune thrombocytopenia (VIPIT). Journal of Thrombosis and Haemostasis, 2021, 19, 1819-1822.	1.9	91
6	Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance. Blood, 2021, 138, 1481-1481.	0.6	6
7	Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. Frontiers in Veterinary Science, 2021, 8, 755258.	0.9	16
8	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1927-1938.	2.7	47
9	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematology,the, 2019, 6, e638-e649.	2.2	101
10	Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. International Journal of Molecular Sciences, 2019, 20, 4233.	1.8	44
11	Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. International Journal of Molecular Sciences, 2019, 20, 2976.	1.8	64
12	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. EBioMedicine, 2019, 50, 111-121.	2.7	14
13	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 81-87.	2.0	42
14	A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML. Leukemia Research, 2019, 78, 36-44.	0.4	3
15	Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 4223-4223.	0.6	1
16	The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica, 2018, 103, 799-809.	1.7	30
17	Major response of PNH to an AML chemotherapy protocol. Annals of Hematology, 2018, 97, 1487-1488.	0.8	1
18	Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. Haematologica, 2018, 103, 1760-1771.	1.7	18

#	Article	IF	Citations
19	The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest. Blood, 2018, 132, 1363-1363.	0.6	2
20	Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica, 2017, 102, 1519-1529.	1.7	36
21	Intensive consolidation with Gâ€CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients â‰¥60 years. American Journal of Hematology, 2017, 92, E567-E574.	2.0	9
22	Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. Journal of Clinical Apheresis, 2017, 32, 224-234.	0.7	28
23	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. Oncotarget, 2017, 8, 23061-23072.	0.8	13
24	Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation. Oncotarget, 2016, 7, 46466-46481.	0.8	19
25	Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56bright NK Cells in Acute Myeloid Leukemia. Blood, 2014, 124, 1422-1422.	0.6	0
26	The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network. Memo - Magazine of European Medical Oncology, 2013, 6, 114-118.	0.3	0
27	Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica, 2013, 98, 1450-1457.	1.7	39
28	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wiener Klinische Wochenschrift, 2012, 124, 807-814.	1.0	33
29	Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nature Chemical Biology, 2012, 8, 905-912.	3.9	96
30	KIT-D816Vâ€“independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood, 2011, 118, 1885-1898.	0.6	64
31	Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536. Cancer Research, 2010, 70, 1513-1523.	0.4	86
32	BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.. Blood, 2010, 116, 3382-3382.	0.6	0
33	Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (ObatoclaxÂ®) on Growth and Viability of Canine and Human Neoplastic Mast Cells. Blood, 2008, 112, 861-861.	0.6	0
34	Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica, 2007, 92, 1451-1459.	1.7	92
35	Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Experimental Hematology, 2007, 35, 1510-1521.	0.2	50
36	Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib. Blood, 2007, 110, 1541-1541.	0.6	6

#	Article	IF	Citations
37	The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.. Blood, 2007, 110, 3554-3554.	0.6	0
38	PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood, 2006, 107, 752-759.	0.6	235
39	Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.. Blood, 2006, 108, 1365-1365.	0.6	1
40	Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.. Blood, 2005, 106, 3516-3516.	0.6	1
41	Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.. Blood, 2005, 106, 3518-3518.	0.6	2
42	Heme Oxygenase-1 (HO-1): A Novel KIT D816V-Dependent Target in Neoplastic Human Mast Cells (HMC-1).. Blood, 2005, 106, 3521-3521.	0.6	1